Huaizhi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huaizhi Wang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Shaohua Hu
Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 shared publications - Saboor Saeed
Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine
6 shared publications - Le Xu
Department of Psychiatry, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China
4 shared publications - Jianbo Lai
Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 shared publications - Xuhong Zhang
Department of Ophthalmology, The First Affiliated Hospital of Zhejiang University, 310003 Hangzhou, Zhejiang, China; School of Medicine, Zhejiang University, 310003 Hangzhou, Zhejiang, China; Nanhu Brain Computer Interface Institute, 310003 Hangzhou, Zhejiang, China
3 shared publications - Dan Wang
Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University
2 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Beyond the role in motor function, entopeduncular nucleus, a critical neural hub in psychiatric disorders and sleep regulation
The EP [1], a critical component of the basal ganglia [2], has emerged as a significant area of interest in neuroscience due to its multifaceted roles in psychiatric disorders, sleep regulation, an...
- 30 July 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Open AccessBeyond the role in motor function, entopeduncular nucleus, a critical neural hub in psychiatric disorders and sleep regulation
The EP [1], a critical component of the basal ganglia [2], has emerged as a significant area of interest in neuroscience due to its multifaceted roles in psychiatric disorders, sleep regulation, an...
- Open Access
- 3 June 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2671594
Circadian rhythms in major depressive disorder: mechanistic insights and therapeutic frontiers
Major Depressive Disorder (MDD) has emerged as a leading cause of disability worldwide, affecting over 264 million people. Recent evidence reveals that disruption of circadian rhythms may be fundamental to MDD pathophysiology, opening new avenues for therapeutic intervention. This review synthesizes current understanding of the intricate relationship between circadian system disruption and MDD, highlighting molecular mechanisms and clinical implications. We examine evidence from genetic studies, clinical observations, and therapeutic trials. Patients with MDD exhibit profound alterations in circadian-regulated processes, including sleep-wake cycles, diurnal mood patterns, and metabolic functions. Genetic studies have identified variants in core clock genes, particularly CLOCK, TIMELESS, and CRY1, that correlate with both circadian disruption and MDD susceptibility. These genetic insights, combined with evidence of dysregulated hypothalamus-pituitary-adrenal axis function and abnormal melatonin signaling, suggest that circadian dysfunction may be causal in MDD pathogenesis rather than merely symptomatic. Emerging chronotherapeutic approaches, such as light therapy, sleep interventions, and targeted pharmacology, show significant potential for improving depressive symptoms. Personalized circadian-based treatments, guided by genetic and molecular markers, could transform MDD care. Advancing our understanding of the circadian-depression connection offers a promising path to revolutionizing treatment strategies.
- 3 June 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2671594
Open AccessCircadian rhythms in major depressive disorder: mechanistic insights and therapeutic frontiers
Major Depressive Disorder (MDD) has emerged as a leading cause of disability worldwide, affecting over 264 million people. Recent evidence reveals that disruption of circadian rhythms may be fundamental to MDD pathophysiology, opening new avenues for therapeutic intervention. This review synthesizes current understanding of the intricate relationship between circadian system disruption and MDD, highlighting molecular mechanisms and clinical implications. We examine evidence from genetic studies, clinical observations, and therapeutic trials. Patients with MDD exhibit profound alterations in circadian-regulated processes, including sleep-wake cycles, diurnal mood patterns, and metabolic functions. Genetic studies have identified variants in core clock genes, particularly CLOCK, TIMELESS, and CRY1, that correlate with both circadian disruption and MDD susceptibility. These genetic insights, combined with evidence of dysregulated hypothalamus-pituitary-adrenal axis function and abnormal melatonin signaling, suggest that circadian dysfunction may be causal in MDD pathogenesis rather than merely symptomatic. Emerging chronotherapeutic approaches, such as light therapy, sleep interventions, and targeted pharmacology, show significant potential for improving depressive symptoms. Personalized circadian-based treatments, guided by genetic and molecular markers, could transform MDD care. Advancing our understanding of the circadian-depression connection offers a promising path to revolutionizing treatment strategies.
- 2 February 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (1) , e70074
Mapping the Global Burden and Inequalities of Bipolar Disorder, 1990–2021, With Projections to 2050: A Systematic Analysis
Background: Bipolar disorder is a severe mental disorder affecting millions worldwide, necessitating comprehensive policies and interventions. Aims: To provide assessment of global inequalities in the burden of bipolar disorder and their projected trajectories to 2050. Methods: Global Burden of Disease 2021 data from 204 countries and territories were analyzed, stratified by age, gender, and Socio‐demographic Index (SDI) quintiles. Age‐standardized prevalence (ASPR), incidence (ASIR), and years lived with disability (ASR YLD) per 100,000 population were calculated. Inequalities were assessed using the slope index of inequality (SII) and concentration index (CI), and ARIMA models were applied to project trends to 2050. Results: From 1990 to 2021, global incidence of BD increased, while prevalence and years lived with disability (YLDs) remained relatively stable (ASPR: 453.7 [95% UI: 381.6–540.8] to 454.6 [95% UI: 377.9–545.8]). Females consistently had higher prevalence than males (474.2 vs. 435.0 per 100,000 in 2021). High‐SDI regions reported the highest rates, with Australasia reaching 1110.8 (95% UI: 940.3–1305.9). The SII for incidence rose slightly (10.87–11.38), while the CI declined (0.096–0.012), indicating increasing absolute but decreasing relative inequalities. Projections suggest a rising global burden, with female prevalence remaining higher and incidence rates converging between genders (global ASIR: 33.8 per 100,000). Conclusion: Global inequalities in bipolar disorder persist, disproportionately affecting females and high‐SDI regions. Projected trends indicate an increasing burden with a narrowing gender gap in incidence, emphasizing the need for targeted interventions and further research on long‐term impacts, including the effects of COVID‐19.
- 2 February 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (1) , e70074
Mapping the Global Burden and Inequalities of Bipolar Disorder, 1990–2021, With Projections to 2050: A Systematic Analysis
Background: Bipolar disorder is a severe mental disorder affecting millions worldwide, necessitating comprehensive policies and interventions. Aims: To provide assessment of global inequalities in the burden of bipolar disorder and their projected trajectories to 2050. Methods: Global Burden of Disease 2021 data from 204 countries and territories were analyzed, stratified by age, gender, and Socio‐demographic Index (SDI) quintiles. Age‐standardized prevalence (ASPR), incidence (ASIR), and years lived with disability (ASR YLD) per 100,000 population were calculated. Inequalities were assessed using the slope index of inequality (SII) and concentration index (CI), and ARIMA models were applied to project trends to 2050. Results: From 1990 to 2021, global incidence of BD increased, while prevalence and years lived with disability (YLDs) remained relatively stable (ASPR: 453.7 [95% UI: 381.6–540.8] to 454.6 [95% UI: 377.9–545.8]). Females consistently had higher prevalence than males (474.2 vs. 435.0 per 100,000 in 2021). High‐SDI regions reported the highest rates, with Australasia reaching 1110.8 (95% UI: 940.3–1305.9). The SII for incidence rose slightly (10.87–11.38), while the CI declined (0.096–0.012), indicating increasing absolute but decreasing relative inequalities. Projections suggest a rising global burden, with female prevalence remaining higher and incidence rates converging between genders (global ASIR: 33.8 per 100,000). Conclusion: Global inequalities in bipolar disorder persist, disproportionately affecting females and high‐SDI regions. Projected trends indicate an increasing burden with a narrowing gender gap in incidence, emphasizing the need for targeted interventions and further research on long‐term impacts, including the effects of COVID‐19.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 1018
How Does Sleep Deprivation Rewrite the Cognitive Function in the Hippocampus?
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 1018
How Does Sleep Deprivation Rewrite the Cognitive Function in the Hippocampus?
- 16 November 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt B) , 120687
Down-regulated expressions of LOC151174, GSTT1, and IFI27L1 in the peripheral blood exhibit the biological and immunological features of major depressive disorder
- 16 November 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt B) , 120687
Down-regulated expressions of LOC151174, GSTT1, and IFI27L1 in the peripheral blood exhibit the biological and immunological features of major depressive disorder
- 6 September 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 392, 120183
Machine learning-enhanced mapping of suicide risk in Bipolar Disorder: A multi-modal analysis
- 6 September 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 392, 120183
Machine learning-enhanced mapping of suicide risk in Bipolar Disorder: A multi-modal analysis
- Open Access
- 3 July 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2517813
The spectrum of overlapping anti-NMDAR encephalitis and demyelinating syndromes: a systematic review of presentation, diagnosis, management, and outcomes
Anti-NMDAR encephalitis frequently overlaps with demyelinating diseases (MOGAD, NMOSD, MS), creating complex syndromes with diverse presentations and challenging management. Systematic search of databases including MEDLINE, Google Scholar, Embase, Scopus, Cochrane Library, and Web of Science up to March 2024 for studies on co-existing anti-NMDAR encephalitis and demyelinating syndromes. Data extracted on clinical characteristics, diagnostics, treatments, and outcomes. Twenty-five studies identified 256 patients (16.2%) with co-existing Anti-NMDAR encephalitis and demyelinating syndromes, primarily MOGAD (94.5%), with fewer cases involving NMOSD or MS. The Anti-NMDAR + MOGAD subgroup exhibited seizures (51-72.7%), psychiatric symptoms (45.5-71.4%), cognitive dysfunction (30.6%), and movement disorders (30.6%). All patients had CSF anti-NMDAR antibodies, with MOG (60%) or AQP4 (25%) antibodies. Use of standardized, cell-based assays and adherence to established criteria are essential to avoid false positives, particularly for MOG. MRI abnormalities were seen in 75% of patients. First-line immunotherapies were effective in 70% of cases; 80% of refractory cases responded to second-line therapies. Anti-NMDAR encephalitis overlapping with demyelinating diseases is challenging. Tailored treatments based on detailed immune profiles are key to better outcomes.
- 3 July 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2517813
Open AccessThe spectrum of overlapping anti-NMDAR encephalitis and demyelinating syndromes: a systematic review of presentation, diagnosis, management, and outcomes
Anti-NMDAR encephalitis frequently overlaps with demyelinating diseases (MOGAD, NMOSD, MS), creating complex syndromes with diverse presentations and challenging management. Systematic search of databases including MEDLINE, Google Scholar, Embase, Scopus, Cochrane Library, and Web of Science up to March 2024 for studies on co-existing anti-NMDAR encephalitis and demyelinating syndromes. Data extracted on clinical characteristics, diagnostics, treatments, and outcomes. Twenty-five studies identified 256 patients (16.2%) with co-existing Anti-NMDAR encephalitis and demyelinating syndromes, primarily MOGAD (94.5%), with fewer cases involving NMOSD or MS. The Anti-NMDAR + MOGAD subgroup exhibited seizures (51-72.7%), psychiatric symptoms (45.5-71.4%), cognitive dysfunction (30.6%), and movement disorders (30.6%). All patients had CSF anti-NMDAR antibodies, with MOG (60%) or AQP4 (25%) antibodies. Use of standardized, cell-based assays and adherence to established criteria are essential to avoid false positives, particularly for MOG. MRI abnormalities were seen in 75% of patients. First-line immunotherapies were effective in 70% of cases; 80% of refractory cases responded to second-line therapies. Anti-NMDAR encephalitis overlapping with demyelinating diseases is challenging. Tailored treatments based on detailed immune profiles are key to better outcomes.
- 2 January 2025
- Published by Elsevier in Neuroscience
- Vol. 567, 294-307
Esketamine alleviates LPS-induced depression-like behavior by activating Nrf2-mediated anti-inflammatory response in adolescent mice
- 2 January 2025
- Published by Elsevier in Neuroscience
- Vol. 567, 294-307
Esketamine alleviates LPS-induced depression-like behavior by activating Nrf2-mediated anti-inflammatory response in adolescent mice
- Open Access
- 25 April 2024
- Published by MDPI AG in Behavioral Sciences
- Vol. 14 (5) , 360
Latent Profile Analysis of Suicidal Ideation in Chinese Individuals with Bipolar Disorder
Individuals with bipolar disorder (BD) have a greater suicide risk than the general population. In this study, we employed latent profile analysis (LPA) to explore whether Chinese individuals with different phases of BD differed at the levels of suicidal ideation. We recruited 517 patients. Depressive symptoms were measured using the 24-item Hamilton Depression Rating Scale (HAMD-24), and manic symptoms were evaluated using the Young Mania Rating Scale (YMRS). The extent of suicidal thoughts was determined through the Beck Scale for Suicide Ideation (BSSI). The scores of HAMD and YMRS were used to perform LPA. LPA categorized participants into three classes: one exhibiting severe depressive and mild manic symptomatology, another showing severe depressive and severe manic symptomatology, and the third one displaying severe depressive and intermediate manic symptomatology. Suicidal ideation levels were found to be remarkably elevated across all three classes. Additionally, the three classes showed no significant differences in terms of suicidal ideation. Our research confirms the link between depressive symptoms and suicide, independent of the manic symptoms. These findings carry meaning as they provide insight into the suicide risk profiles within different phases of BD.
- 25 April 2024
- Published by MDPI AG in Behavioral Sciences
- Vol. 14 (5) , 360
Open AccessLatent Profile Analysis of Suicidal Ideation in Chinese Individuals with Bipolar Disorder
Individuals with bipolar disorder (BD) have a greater suicide risk than the general population. In this study, we employed latent profile analysis (LPA) to explore whether Chinese individuals with different phases of BD differed at the levels of suicidal ideation. We recruited 517 patients. Depressive symptoms were measured using the 24-item Hamilton Depression Rating Scale (HAMD-24), and manic symptoms were evaluated using the Young Mania Rating Scale (YMRS). The extent of suicidal thoughts was determined through the Beck Scale for Suicide Ideation (BSSI). The scores of HAMD and YMRS were used to perform LPA. LPA categorized participants into three classes: one exhibiting severe depressive and mild manic symptomatology, another showing severe depressive and severe manic symptomatology, and the third one displaying severe depressive and intermediate manic symptomatology. Suicidal ideation levels were found to be remarkably elevated across all three classes. Additionally, the three classes showed no significant differences in terms of suicidal ideation. Our research confirms the link between depressive symptoms and suicide, independent of the manic symptoms. These findings carry meaning as they provide insight into the suicide risk profiles within different phases of BD.
- Open Access
- 5 April 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 71, 102581
Effect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: a network meta-analysis of randomised-controlled trials
- 5 April 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 71, 102581
Open AccessEffect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: a network meta-analysis of randomised-controlled trials